Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Wang, Jiandong ^a   Ma, Xiaoli ^a   Jones, Hannah M ^b   Chan, Leo Li Ying ^c   Song, Fang ^a   Zhang, Weiyuan ^a   Bae Jump, Victoria L ^b   Zhou, Chunxiao ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Nexcelom Bioscience LLC   (United States)

Author keywords

10058 F4; c Myc; Ovarian cancer; Primary cell culture; Therapeutics

Indexed keywords

10058 F4; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; MAX PROTEIN; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN, HUMAN; MYC PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLONY FORMATION; CONTROLLED STUDY; DIMERIZATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OVARY CARCINOMA; PRIMARY CULTURE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROTEIN MULTIMERIZATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; THIAZOLES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84910030717     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0226-x     Document Type: Article

References (33)

1. Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì A, Virzì S, Puccio F, Ravenda PS, Kusamura S. Advanced cytoreduction as surgical standard of care and hyperthermicintraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 2011, 37(1):4-9. 10.1016/j.ejso.2010.11.004, 21112721.
2. Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 2010, 118(1):88-92. 10.1016/j.ygyno.2010.03.012, 20439111.
3. Joo WD, Lee JY, Kim JH, Yoo HJ, Roh HJ, Park JY, Kim DY, Kim YM, Kim YT, Nam JH. Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol 2009, 20(2):96-100. 10.3802/jgo.2009.20.2.96, 19590720.
4. Skírnisdóttir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 2011, 21(2):236-244. 10.1097/IGC.0b013e31820986e5, 21270607.
5. Dang CV. MYC on the path to cancer. Cell 2012, 149(1):22-35. (review), 10.1016/j.cell.2012.03.003, 22464321.
6. Le A, Dang CV. Studying Myc's role in metabolism regulation. Methods Mol Biol 2013, 1012:213-219. 10.1007/978-1-62703-429-6_14, 24006067.
7. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003, 22:6151. 10.1038/sj.onc.1206641, 13679853.
8. Gomez-Curet I, Perkins RS, Bennett R, Feidler KL, Dunn SP, Krueger LJ. c-Myc inhibition negatively impacts lymphoma growth. J Pediatric Surg 2006, 41(1):207-211. 10.1016/j.jpedsurg.2005.10.025.
9. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006, 34(11):1480-1489. 10.1016/j.exphem.2006.06.019, 17046567.
10. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 2007, 18(2):161-170. 10.1097/CAD.0b013e3280109424, 17159602.
11. Zhang QL, Luo CL, Wu XH, Wang CY, Xu X, Zhang YY, Liu Q, Shen SL. HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem 2011, 112(10):2910-2919. 10.1002/jcb.23207, 21618595.
12. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 2010, 10:248. 10.1186/1471-2407-10-248, 20515470.
13. Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol 2009, 174:1037-1047. 10.2353/ajpath.2009.080735, 19179604.
14. He C, Rong R, Liu J, Wan J, Zhou K, Kang JX. Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells. Chin Med 2012, 30(7(1)):11. 10.1186/1749-8546-7-11.
15. Teicher BA. In vivo/ex vivo and in situ assays used in cancer research: a brief review. Toxicol Pathol 2009, 37(1):114-122. 10.1177/0192623308329473, 19098118.
16. Gatti G, Maresca G, Natoli M, Florenzano F, Nicolin A, Felsani A, Agnano I. MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS One 2009, 4(5):e5442. 10.1371/journal.pone.0005442, 19421315.
17. Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D, Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett 2008, 266(1):12-20. 10.1016/j.canlet.2008.02.028, 18378391.
18. O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, Dang CV. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006, 26(6):2373-2386. 10.1128/MCB.26.6.2373-2386.2006, 16508012.
19. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ, Prochownik EV. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007, 6(9):2399-2408. 10.1158/1535-7163.MCT-07-0005, 17876039.
20. Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, MunksgaardPersson M, Hultenby K, Lehtiö J, Einvik C, Påhlman S, Kogner P, Jakobsson PJ, Henriksson MA. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A 2013, 110(25):10258-10263. 10.1073/pnas.1222404110, 23733953.
21. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 2010, 15(4):2886-2910. 10.3390/molecules15042886, 20428086.
22. Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, Sattler UG. Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 2012, 279(5):882-891. 10.1111/j.1742-4658.2012.08479.x, 22240028.
23. Priebe A, Tan L, Wahl H, Kueck A, He G, Kwok R, Opipari A, Liu JR. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol 2011, 122(2):389-395. 10.1016/j.ygyno.2011.04.024, 21570709.
24. Ellenberger LD, Bruin JE, Greenaway J, Campbell NE, Moorhead RA, Holloway AC, Patrick J. The role of deregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010, 2010:514310.
25. Zhou Y, Tizzy F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widget W, Ellis LM, Wei HZ. Intracellular ATP levels are a pivotal determinant of chemo resistance in colon cancer cells. Cancer Res 2012, 72(1):304-314. 10.1158/0008-5472.CAN-11-1674, 22084398.
26. Valera A, Pool A, Gregory X, RI E, Visa J, Bosch F. Evidence from transgenic mice that my regulates hepatic glycolysis. FASEB J 1995, 9(11):1067-1078. 7649406.
27. Kim J-W, Gao P, Liu Y-C, Semen GL, Dang CV. Hypoxia-Inducible Factor 1 and Deregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1. Mol Cell Biol 2007, 27(21):7381-7393. 10.1128/MCB.00440-07, 17785433.
28. Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, Enge M, Kel A, Selivanova G. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem 2011, 286(48):41600-41615. 10.1074/jbc.M111.240812, 21862591.
29. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012, 18(20):5546-5553. 10.1158/1078-0432.CCR-12-0977, 23071356.
30. Haglund C, Aleskog A, Nygren P, Gullbo J, Höglund M, Wickström M, Larsson R, Lindhagen E. In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemother Pharmacol 2012, 69(3):697-707. 10.1007/s00280-011-1746-1, 21984220.
31. O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001, 83(2):334-342. 10.1006/gyno.2001.6395, 11606094.
32. Herzog TJ, Kiva TC, Fader AN, Coleman RL. Chemosensitivity testing with Chemo and overall survival in primary ovarian cancer. Am J Oster Gynecol 2010, 203(1):68.
33. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006, 16(1):194-201. 10.1111/j.1525-1438.2006.00301.x, 16445633.